What leaders in the field are looking forward to:

"siRNA are emerging drugs enabling the treatment of diseases with unmet medical needs. However, challenges need to be addressed to expand the use of siRNA to treat diseases beyond liver. Taking part in this meeting which is only focused on RNAi based therapeutics will offer the opportunity to dive in depth on the challenges and solutions to improve siRNA therapeutics"

Annabelle Biscans, Associate Principle Scientist
AstraZeneca R&D

Photo Biscans

Annabelle Biscans, Associate Principle Scientist
AstraZeneca R&D

Xiaobo Zhong, Professor of Pharmacology & Toxicology,
University of Connecticut

Xiaobo-Zhong-4x6-005

"The summit can serve as a platform to exchange most advanced knowledge on RNAi-based therapeutics for new drug discovery and development as well as clinical practice for current FDA-approved siRNA drugs."

Xiaobo Zhong, Professor of Pharmacology & Toxicology,
University of Connecticut

 

 

Robert Shaffer, Founder & COO, 
Vrata Therapeutics

 

1587581774543

"Comprehensive program that enables sharing and discussion of best practices across many aspects of RNAi development"

Robert Shaffer, Founder & COO, 
Vrata Therapeutics

 

 

"It is a great chance to communicate with both academic and industrial experts in RNAi therapeutics to improve its application in human diseases.  I anticipate that the meeting will be a big success."

Ying Yu, Associate Director, 
AbbVie

 

 

1516521538658

Ying Yu, Associate Director, 
AbbVie

 

 

 

Peter Goughnour, Director of R&D, 
Curigin

 

 

 

my picture

"The value of taking part would be building relationships with other members in our field with potential collaborations"

Peter Goughnour, Director of R&D, 
Curigin